louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03163862: G-CSF Administration in IVF in a Preferable Preceptive Endometrium Score
Official title: Granulocyte Stimulating Factor (G-CSF) to Increase the Rate of Implantation Success in IVF Patients in Preferable Preceptive Endometrium Scroe
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
PHASE3
Conditions: Women Infertility
Keywords: IVF
Lead sponsor: Istishari Arab Hospital
Sponsor class: OTHER
Collaborators: name: Salem Abu Khyzaran
name: Nizam Najeeb
First posted: 2017-05-23
Enrollment: 100
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: This is a controlled preminary trial intended to increase the implantation rate of IVF cycles, by using more than one known procedure, endometrial scratching, evaluating the status of the adhesive factors as αVβ3 integrin, L-selectin ligand MECA-79, E-cadherin and ICAM-1, as a determinant for intervention by G-CSF, according to a score that can be done on a small sample obtained during scratching, then give G-CSF for the scores less than 4 intrauterine and subcutaneously.

Detailed description: Placebo: CONTROL patients treated with PLACEBO (saline solution) from the day of embryo transfer through the day of beta hCG test Drug\& scratching CONTROL saline infusion every day from the day of embryo transfer through the day of beta HCG test Other Name: SALINE INFUSION Experimental: G-CSF group patients treated with G-CSF if the biopsy adhesive score 1-3 only

1. Endometrial scratching and adhesive factor score, day 21-24 cycle prior to IVF//0rv day 3 of IVF cycle not planned before.
2. Drug \&scratching : G-CSF group

1- 300 µg trans cervical intrauterine of G-CSF was administered at the oocyte retrieval day, 2- subcutaneous 300 micrograms G-CSF on the day of embryo transfer Comparative group patients not treated with G-CSF after scratching if the biopsy adhesive score 4 only

Scratching only :

Patients undergoing scratching on day 21-24 of prior IVF cycle/ and on day 5 of IVF cycle with biopsy score of 4.

Eligibility criteria: Inclusion Criteria:

* ALL Women aged \< 40 years who would be submitted to oocyte retrieval and embryo transfer IN IVF cycle.

Exclusion Criteria:

* • contraindications for G-CSF treatment (sickle cell disease, chronic neutropenia, known past or present malignancy, renal insufficiency, upper respiratory infection, pneumonia, and congenital fructose intolerance)

Primary outcomes:
measure: clinical pregnancy per women randomized
timeFrame: 4 weeks
Secondary outcomes:
measure: setting a score of precepative endometrium
timeFrame: 12 months
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06812962: A Pilot RCT on the Feasibility of an Online Quiz Game to Promote Tobacco-related Knowledge, Attitudes and Behaviours Among Primary School Students
Official title: A Pilot RCT on the Feasibility of an Online Quiz Game to Promote Tobacco-related Knowledge, Attitudes and Behaviours Among Primary School Students
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Tobacco Prevention
Lead sponsor: The University of Hong Kong
Sponsor class: OTHER
First posted: 2025-02-06
Enrollment: 921
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The goal of this pilot RCT is to test the feasibility of an online quiz game to promote tobacco-related knowledge, attitudes and behaviours in local primary 5-6 school students. The main question it aims to answer is:

* Feasibility of intervention
* Acceptance of intervention by schools, teachers, parents and teachers
* Adherence to the 4-week intervention
* Functional online quiz platform
* Satisfaction of students and parents towards intervention Researchers will compare the questionnaire results from students to see if students doing tobacco-related questions on the online quiz platform will have better tobacco-related knowledge, higher anti-tobacco attitudes and lower intention to smoke.

Students will engage in an online quiz competition for 4 weeks on tobacco-related topics for the intervention group and on healthy eating for the control group. They will complete pre-test and post-test questionnaires before and after the online quiz competition.


Eligibility criteria: Inclusion Criteria:

* Primary 5-6 students from local primary schools
* Able to read and communicate in Chinese
* Have a digital device for online access to the quiz game at home

Exclusion Criteria:

-

Primary outcomes:
measure: Feasibility of intervention
timeFrame: During the post-questionnaire at 5th-6th weeks and during the phone interview at 10th-16th weeks.
Secondary outcomes:
measure: Effectiveness of intervention on tobacco-related knowledge (including ASPs)
timeFrame: During the pre-questionnaire right before the intervention and post-questionnaire at 5th-6th weeks.
measure: Effectiveness of intervention on tobacco-related attitudes (including ASPs)
timeFrame: During the pre-questionnaire right before the intervention and post-questionnaire at 5th-6th weeks.
measure: Effectiveness of intervention on tobacco-related intentions (including ASPs)
timeFrame: During the pre-questionnaire right before the intervention and post-questionnaire at 5th-6th weeks.
measure: Effectiveness of intervention on SHS and THS exposure at home
timeFrame: During the pre-questionnaire right before the intervention and post-questionnaire at 5th-6th weeks.
measure: Effectiveness of intervention on tobacco use
timeFrame: During the pre-questionnaire right before the intervention and post-questionnaire at 5th-6th weeks.
Other outcomes:
Locations:
city: Hong Kong
country: Hong Kong
facility: Local primary schools
Study officials:
References:
Clinical trial NCT02314962: PET/MRI Perfusion and CT Perfusion in Solid Tumors
Official title: Diagnostic and Clinical Accuracy of Integrated Magnetic Resonance Imaging and Computed Tomography Perfusion in PET/MRI in Comparison to PET/CT in Solid Tumors
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: CT Perfusion and MRI Perfusion in Solid Tumors
Lead sponsor: University of Zurich
Sponsor class: OTHER
First posted: 2014-12-11
Enrollment: 43
Sex: ALL
Minimum age (years): 30
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with suspected or confirmed solid malignant tumors of the neck, chest or abdomen who have an indication for a PET/CT

Brief summary: Diagnostic comparison between PET/CT and PET/MRI with integrated perfusion measurement in CT and MR. Study aim is to gain knowledge about additional value of CT perfusion and MR perfusion in solid tumors concerning tumor physiology, diagnostic accuracy and possibly prognostic.


Eligibility criteria: Inclusion Criteria:

* indication as stated above
* written informed consent
* patients with suspected or confirmed solid malignant tumors of the neck, chest or abdomen who have an indication for a PET/CT

Exclusion Criteria:

* pregnant or breast feeding women
* non compliance of the patient to follow the study instructions (e.g. hearing problems, dementia)
* Inclusion in another clinical trial 30 days prior to inclusion
* age \< 30years
* contraindication for MRI (cardiac pacemaker, certain metal implants, claustrophobia
* known allergies to contrast CT or MRI contrast media
* patients with an glomerular filtration rate of \< 60ml/min/1.73m2

Primary outcomes:
measure: Measurement of blood flow, blood volume and transfer constant (Ktrans) with CT-Perfusion and PET/MR-perfusion in solid tumors.
timeFrame: 18 months
Secondary outcomes:
measure: Correlation of blood flow, blood volume and transfer constant (Ktrans) measured with CT-Perfusion and PET/MR-perfusion with progression free survival in solid tumors.
timeFrame: 18 months
Other outcomes:
measure: Measurement of blood flow (mL/100 mg tissue/min) with CT-Perfusion and PET/MR-perfusion in solid tumors.
timeFrame: 18 months
measure: Measurement of blood volume (mL/100 mg tissue) with CT-Perfusion and PET/MR-perfusion in solid tumors.
timeFrame: 18 months
measure: Measurement of transfer constant with PET/MR-perfusion in solid tumors.
timeFrame: 18 months
Locations:
city: Zurich
country: Switzerland
facility: University Hospital Zurich, Diagnostic and Interventional Radiology
state: ZH
Study officials:
affiliation: University Hospital Zurich, Diagnostic and Interventional Radiology
name: Patrick Veit-Haibach, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00600262: Intravitreal Bevacizumab for Diabetic Retinopathy
Official title: Efficacy of Intravitreal Bevacizumab for Severe Nonproliferative and Proliferative Diabetic Retinopathy.
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
PHASE3
Conditions: Severe Nonproliferative
Proliferative Diabetic Retinopathy
Active Photocoagulated Diabetic Retinopathy
Keywords: severe nonproliferative
proliferative diabetic retinopathy
active photocoagulated diabetic retinopathy
intravitreal bevacizumab
Lead sponsor: Asociación para Evitar la Ceguera en México
Sponsor class: OTHER
First posted: 2008-01-24
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Background: to evaluate the 3-month efficacy of a single dose of intravitreal bevacizumab on the progression of severe non proliferative diabetic retinopathy, proliferative diabetic retinopathy and active photocoagulated diabetic proliferative by evaluation of ischemic areas and regression of retinal and disc neovasculrization.

Methods: 40 patients were enrolled in a prospective, interventional study. Patients were treated with intravitreal bevacizumab 0.1ml (0.25mg). We evaluated visual acuity, neovascularization leakage points, capillary closure ischemic areas and macular edema by clinical examination and fluorescein angiography. A clinical examination was performed at baseline and days 1,14 and 30. Active leakage points were measured by fluorescein angiography at 30 days.


Eligibility criteria: Inclusion Criteria:

* Severe nonproliferative
* Proliferative diabetic retinopathy
* Active photocoagulated diabetic retinopathy

Exclusion Criteria:

* Previous vascular occlusion
* Glaucoma
* Uncontrolled hypertension, thromboembolic event
* Renal abnormalities
* Recent or planned surgery
* Coagulation abnormalities
* Panretinal photocoagulation of less than one month before
* Patients with known serious allergies

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Mexico City
country: Mexico
facility: Elizabeth Reyna Castelan
Study officials:
affiliation: Asociación para evitar la ceguera en Mexico
name: Elizabeth Reyna-Castelan, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Asociación para Evitar la Ceguera en México
name: Mariana Martinez-Castellanos, MD
role: STUDY_CHAIR
References:
Clinical trial NCT02386462: Determine the ED50 of Dexmedetomidine to Facilitate LMA Insertion During Anaesthesia Induction
Official title: To Determine the Median Effective Dose (ED50) of Dexmedetomidine to Facilitate LMA Insertion During Anaesthesia Induction With Propofol 2.0 mg/kg
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Anesthesia
Keywords: laryngeal mask airway
circulatory reflexes
Lead sponsor: Guangzhou General Hospital of Guangzhou Military Command
Sponsor class: OTHER
First posted: 2015-03-12
Enrollment: 30
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Dexmedetomidine can be used as a co-induction agent to facilitate laryngeal mask airway (LMA) insertion with minimal effect on respiratory function. The purpose of the study was to determine the median effective dose (ED50) of dexmedetomidine to facilitate LMA insertion during anaesthesia induction with propofol 2.0 mg/kg.

Detailed description: Dexmedetomidine is a highly selective α2 receptor agonist, which produces sedative, anxiolytic and analgesic effects without causing clinically significant respiratory depression. Dexmedetomidine also reduces the propofol requirement for sedation and anaesthesia induction. Therefore, dexmedetomidine may be a useful co-induction agent to facilitate LMA insertion with minimal effects on respiratory function. A recent study showed that dexmedetomidine administration prior to propofol induction provided similar conditions for successful LMA insertion, as does fentanyl without respiratory depression. The purpose of this study was to determine the median effective dose (ED50) of dexmedetomidine required for successful LMA insertion during induction with propofol of 2 mg/kg .

Eligibility criteria: Inclusion Criteria:

1. ASA Ⅰ \~ Ⅱ women undergoing Laparoscopic surgery.
2. Written informed consent from the patient or the relatives of the participating patient.
3. BMI:18.5～25

Exclusion Criteria:

1. Mental illness can not match
2. epidural anesthesia contraindicated
3. People who have Slow-type arrhythmias
4. Chronic renal failure
5. Alcohol or drug abuse
6. Already taking gabapentin, pregabalin, benzodiazepin or antidepression drug

Primary outcomes:
measure: The assessment of sedation (determine the effect-site dose of dexmedetomidine blunting cardiovascular responses to the insertion of the laryngeal mask airway at the same level of sedation)
timeFrame: 5min after the end of the infusion
Secondary outcomes:
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Guangzhou Military Region General Hospital, Department of Anesthesiology
state: Guangdong
Study officials:
References:
Clinical trial NCT03959462: Supporting Decisions With Transcranial Direct Current Stimulation in Healthy Young and Elderly Individuals
Official title: Supporting Decisions With Transcranial Direct Current Stimulation in Healthy Young and Elderly Individuals
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Real tDCS
Sham tDCS
Keywords: tDCS
Lead sponsor: University of Bern
Sponsor class: OTHER
Collaborators: name: Novartis
First posted: 2019-05-22
Enrollment: 254
Sex: ALL
Minimum age (years): 20
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Participants are allocated to one of 2 groups: real tDCS or sham.
Primary purpose: BASIC_SCIENCE

Brief summary: Decisions are part of the daily life. On the neuronal level, activity in the dorsolateral prefrontal cortex (dlPFC) is important during complex decisions (e.g., whether something is emotional for a person or not). We apply transcranial direct current stimulation (tDCS) with the aim to increase dlPFC activity and thereby modulate decisions towards emotional content.


Eligibility criteria: Inclusion Criteria:

* Written informed consent
* Non-smokers
* Right-handedness
* Native German speakers or comparable level of fluency
* Normal or corrected-to-normal vision

Exclusion Criteria:

* Neurological or psychiatric condition (other than diagnosed cognitive impairment)
* Past head injuries
* Magnetizable implants
* History of seizures
* Current or life-time alcohol or drug abuse
* Skin diseases
* tES in the 3 months preceding or during the present study
* Caffeine 3 hours prior to training

Primary outcomes:
measure: Influence of Stimulation on the Decisions
timeFrame: 10 minutes
Secondary outcomes:
measure: Profile of Mood States (POMS; before stimulation)
timeFrame: 3 minutes
measure: Profile of Mood States (POMS; after stimulation)
timeFrame: 3 minutes
measure: Positive and Negative Affect Schedule (PANAS; before stimulation)
timeFrame: 2 minutes
measure: Positive and Negative Affect Schedule (PANAS; after stimulation)
timeFrame: 2 minutes
Other outcomes:
Locations:
city: Bern
country: Switzerland
facility: Klinik für Alterspsychiatrie und Psychotherapie UPD Bern
Study officials:
affiliation: Universitäre psychiatrische Dienste Bern (UPD), University of Bern
name: Jessica Peter, PD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03224962: Reliability of Fluorescent Camera in Diagnosis of Occlusal Carious Lesion
Official title: Reliability of Fluorescent Camera and Caries Detection Dye Versus Visual- Assessment in Diagnosis of Occlusal Carious Lesion in Adult Patients: Invivo Diagnostic Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Caries
Keywords: pit and fissure caries
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2017-07-21
Enrollment: 43
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult populations suffering from occlusal caries.

Brief summary: This study will be conducted to compare the diagnostic predictive values of a light induced fluorescence camera and Caries detection dye versus visual assessment method in identification of occlusal carious lesion.

Detailed description: A total of 43 volunteer patients will be assigned in this study. Each patient must have at least two occlusal carious lesions. Each lesion will be evaluated by three diagnostic methods (D), where D1 represents light induced fluorescence camera, D2 represents Caries detection dye. And D3 represents visual assessment method (ICDAS criteria)

Eligibility criteria: Inclusion Criteria:

* Patients should be over 18 Years old
* Patient should have good oral hygiene and general health
* patients With at least 2 non-cavitated first and/or second molar teeth in each quadrant of maxilla or mandible

Exclusion Criteria:

* Known allergy to any component of the dyes used.
* Patients having caries at proximal, buccal, lingual surface.
* Previously placed sealants or restorations.
* Bruxism or malocclusion

Primary outcomes:
measure: Reliability and level of agreement between operators for all diagnostic methods.
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Conservative Dentistry Department, Faculty of Oral and Dental Medicine, Cairo University, Egypt.
name: Mona I Riad, Professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00947362: Rationale for New Topical Anthroponotic Cutaneous Leishmaniasis (ACL) Treatment in Kabul
Official title: Phase 2 Study Electrothermocauterisation of Afghan Patients With Anthroponotic Cutaneous Leishmaniasis With and Without Pharmaceutical Chlorite Listed in the German Drug Codex (DAC N-055)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Wound Healing
Lead sponsor: Waisenmedizin e. V. Promoting Access to Essential Medicine
Sponsor class: OTHER
Collaborators: name: Waisenmedzin eV PACEM non-profit German NGO
name: German Medical Service (GMS) in Kabul
name: University of Freiburg
name: Microbiology Institute Clinical Microbiology Immunology and Hygiene University Clinic of Erlangen Germany
First posted: 2009-07-28
Enrollment: 134
Sex: ALL
Minimum age (years): 5
Standard ages: CHILD
ADULT
OLDER_ADULT
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of the randomized double blind trial with 134 patients presenting old world cutaneous leishmaniasis is:

* to evaluate the clinical efficacy of electro-thermo-cauterisation (ETC) followed by moist wound treatment versus ETC followed by moist wound treatment plus 0.05 % pharmaceutical chlorite that has been used in three European countries (Germany, Austria and Switzerland) in wound care management for more than 20 years;
* to judge whether early wound care management would present a viable improvement to the actual anti-parasitic treatments mostly neglecting the chronic wound problem and to evaluate its long-term effect on immunity through relapse control 6 months after wound healing.


Eligibility criteria: Inclusion Criteria:

* at least one suspected lesion positive in Giemsa smear

Exclusion Criteria:

* patients previously treated for leishmania

Primary outcomes:
measure: Wound closure time
Secondary outcomes:
measure: Leishmania load parasites per gram of tissue before and after treatment
Other outcomes:
Locations:
city: Kabul
country: Afghanistan
facility: German Medical Service
Study officials:
References:
citation: Jebran AF, Schleicher U, Steiner R, Wentker P, Mahfuz F, Stahl HC, Amin FM, Bogdan C, Stahl KW. Rapid healing of cutaneous leishmaniasis by high-frequency electrocauterization and hydrogel wound care with or without DAC N-055: a randomized controlled phase IIa trial in Kabul. PLoS Negl Trop Dis. 2014 Feb 13;8(2):e2694. doi: 10.1371/journal.pntd.0002694. eCollection 2014 Feb.
Clinical trial NCT02318862: Assessment of Esophageal Epithelium Integrity With Mucosal Impedance
Official title: Assessment of Esophageal Epithelium Integrity With Mucosal Impedance
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Gastroesophageal Reflux Disease (GERD)
Non-erosive Reflux Disease (NERD)
Keywords: reflux
GERD
EGD
pH testing
Lead sponsor: Vanderbilt University Medical Center
Sponsor class: OTHER
First posted: 2014-12-17
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Gastroesophageal reflux disease (GERD) is a common condition affecting more than 100 million adults in the U.S., and it significantly impacts patients' quality of life while imposing billions of dollars of direct and indirect costs each year upon our healthcare system. Current diagnostic tests for GERD are highly invasive and medically inadequate, and the goal of this project is to develop a novel, minimally invasive Mucosal Impedance technique for more accurate detection of GERD while reducing costs.


Eligibility criteria: Inclusion Criteria:

* Patients undergoing standard of care EGD with 48-hr pH testing by BRAVO
* Previous diagnosis of reflux
* At least 18 years of age

Exclusion Criteria:

* Those less than 18 years of age
* Unable to give informed consent
* Use of acid suppressive therapy within the last 10 days
* Known history of Barrett's esophagus, gastric surgery, alcoholism, or significant motility condition

Primary outcomes:
measure: Measurement of lower esophageal impedance using mucosal impedance catheter
timeFrame: During standard of care EGD
Secondary outcomes:
Other outcomes:
Locations:
city: Nashville
country: United States
facility: Vanderbilt University Medical Center
state: Tennessee
Study officials:
affiliation: Vanderbilt University Medical Center
name: Michael Vaezi, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: